Neurometabolites and Antipsychotic Response in Psychosis
2026 · DOI
The association between childhood Toxoplasma gondii, psychotic experiences and grey matter volume: A population-based cohort study
2026 · DOI
Increased Brain-Age Gap in Young Adults With Psychotic Experiences
2026 · DOI
Inflammatory markers (IL-6 and CRP) in childhood and their association with brain structure and psychotic experiences in adulthood
2026 · DOI
1 H-MRS metabolites in antipsychotic-responsive versus non-responsive psychosis: a meta- and mega-analysis
2025 · DOI
Neurometabolites in Antipsychotic-Responsive Versus Non-Responsive Psychosis: A Meta-Analysis
2025 · DOI
PSYSCAN multi-centre study: baseline characteristics and clinical outcomes of the clinical high risk for psychosis sample
2025 · DOI
521. Neurometabolites in Antipsychotic-Responsive Versus Non-Responsive Psychosis: A Meta-Analysis
2025 · DOI
Molecular and micro-architectural mapping of gray matter alterations in psychosis
2025 · DOI
Head circumference trajectories in autism and psychotic experiences
2025 · DOI
A Longitudinal Study of Head Circumference Trajectories in Autism and Autistic Traits
2024 · DOI
Multivariable prediction of functional outcome after first-episode psychosis: a crossover validation approach in EUFEST and PSYSCAN
2024 · DOI
Exploring causal mechanisms of psychosis risk
2024 · DOI
White Matter Microstructure Abnormalities in Individuals at High Risk for Psychosis: A Meta-Analysis of Fractional Anisotropic Changes Associated With Transition to Psychosis
2024 · DOI
Variability and Magnitude of Brain Glutamate Levels in Schizophrenia: A Meta and Mega-Analysis
2024 · DOI
A letter to the editor: The effects of alcohol use on brain glutamate in first episode psychosis
2024 · DOI
The impact of cumulative obstetric complications and childhood trauma on brain volume in young people with psychotic experiences
2023 · DOI
Variability and magnitude of brain glutamate levels in schizophrenia: a meta and mega-analysis
2023 · DOI
Do brain regions involved in threat processing mediate the association between developmental trauma and psychosis
2023 · DOI
Molecular and micro-architectural mapping of gray matter alterations in psychosis
2023 · DOI
Identifying Electroencephalography Biomarkers in Individuals at Clinical High Risk for Psychosis in an International Multi-Site Study
2022 · DOI
Do brain regions associated with memory processing mediate the relationship between developmental trauma and psychosis?
2022 · DOI
Reduced amygdala volume mediates the association between developmental trauma and psychotic experiences in adulthood – findings from a population-based cohort
2022 · DOI
Variability and Magnitude of Brain Glutamate Levels in Schizophrenia: A Meta And Mega-Analysis
2022 · DOI
Dopamine and glutamate in individuals at high risk for psychosis: a meta‐analysis of in vivo imaging findings and their variability compared to controls
2021 · DOI
Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level: a Mega-analysis of Individual Participant-Level Data
2021 · DOI
Longitudinal Structural MRI Findings in Individuals at Genetic and Clinical High Risk for Psychosis: A Systematic Review
2021 · DOI
Symptom Remission and Brain Cortical Networks at First Clinical Presentation of Psychosis: The OPTiMiSE Study.
2020 · DOI
Glyceryl trinitrate in first-episode psychosis unmedicated with antipsychotics: A randomised controlled pilot study.
2020 · DOI
M157. A MULTICENTRE STUDY OF 1H-MRS BRAIN GLUTAMATE LEVELS IN SCHIZOPHRENIA; INVESTIGATING THE EFFECT OF ANTIPSYCHOTIC MEDICATION, SYMPTOM SEVERITY AND AGE
2020 · DOI
T40. GLYCERYL TRINITRATE IN FIRST EPISODE PSYCHOSIS UNMEDICATED WITH ANTIPSYCHOTICS: A RANDOMISED CONTROLLED FEASIBILITY STUDY
2020 · DOI
A MULTICENTRE STUDY OF 1H-MRS BRAIN GLUTAMATE LEVELS IN SCHIZOPHRENIA; INVESTIGATING THE EFFECT OF ANTIPSYCHOTIC MEDICATION, SYMPTOM SEVERITY AND AGE
2020 ·
Towards Precision Medicine in Psychosis: Benefits and Challenges of Multimodal Multicenter Studies-PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice
2020 · DOI
Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate.
2019 · DOI
REMISSION FROM ANTIPSYCHOTIC TREATMENT IN FIRST EPISODE PSYCHOSIS RELATED TO LONGITUDINAL CHANGES IN BRAIN GLUTAMATE LEVELS
2019 · DOI
Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre 1H-MRS study (OPTiMiSE)
2018 · DOI
Effects of Antipsychotic Administration on Brain Glutamate in Schizophrenia: A Systematic Review of Longitudinal 1H-MRS Studies
2017 · DOI
SA83. Brain Glutamate Levels and Antipsychotic Response in Schizophrenia
2017 · DOI
BRAIN GLUTAMATE LEVELS AND ANTIPSYCHOTIC RESPONSE IN SCHIZOPHRENIA
2017 ·
NATURE OF GLUTAMATE ALTERATIONS IN SCHIZOPHRENIA: A META-ANALYSIS OF PROTON MAGNETIC RESONANCE SPECTROSCOPY STUDIES
2017 ·
Nature of Glutamate Alterations in Schizophrenia: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies.
2016 · DOI
Relationship Between Brain Glutamate Levels and Clinical Outcome in Individuals at Ultra High Risk of Psychosis
2014 · DOI
RELATIONSHIP BETWEEN BRAIN GLUTAMATE CONCENTRATIONS AND FUNCTIONAL OUTCOME IN INDIVIDUALS AT ULTRA HIGH RISK OF PSYCHOSIS
2014 · DOI
THE REPRODUCIBILITY OF 1H-MRS GLUTAMATE CONCENTRATION ESTIMATES AT 3 TESLA, IMPLICATIONS FOR GLUTAMATE IMAGING IN SCHIZOPHRENIA
2014 · DOI
Relationship between glutamate dysfunction and symptoms and cognitive function in psychosis
2013 · DOI
The Effect of Developmental Trauma on Brain Structures Involved in Threat and Memory Processing and Its Relation to Psychotic Experiences in Adulthood
· DOI